5 Best Small-Cap Growth Stocks to Buy Now

2. Akero Therapeutics, Inc. (NASDAQ:AKRO)

Number of Hedge Fund Investors in Q4 2022: 32

Akero Therapeutics, Inc. (NASDAQ:AKRO) is a biotechnology firm operating out of San Francisco, California. It develops treatments for metabolic disorders including those that manage cellular stress and the processing of carbohydrates and proteins. Akero Therapeutics, Inc. (NASDAQ:AKRO) is a relatively young company since it was set up in 2017.

After looking at 943 hedge funds for their fourth quarter of 2022 shareholdings, Insider Monkey found that 32 had invested in the firm. Akero Therapeutics, Inc. (NASDAQ:AKRO)’s largest shareholder is David Witzke and Michael Gregory’s Avidity Partners Management with a $209 million stake.

Follow Akero Therapeutics Inc. (NASDAQ:AKRO)